Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel Therapies in IBS-D Treatment.
Nee J, Zakari M, Lembo AJ. Nee J, et al. Among authors: zakari m. Curr Treat Options Gastroenterol. 2015 Dec;13(4):432-40. doi: 10.1007/s11938-015-0068-5. Curr Treat Options Gastroenterol. 2015. PMID: 26432092
Clinical and manometric characteristics of women with paradoxical puborectalis syndrome.
Rangan V, Zakari M, Hirsch W, Ballou S, Singh P, Sommers T, Iturrino J, Nee J, Staller K, Lembo A. Rangan V, et al. Among authors: zakari m. United European Gastroenterol J. 2018 Dec;6(10):1578-1585. doi: 10.1177/2050640618798227. Epub 2018 Sep 3. United European Gastroenterol J. 2018. PMID: 30574329 Free PMC article.
Decorin alleviates non-alcoholic fatty liver disease in rats with polycystic ovary syndrome.
Elkattawy HA, Alsemeh AE, Ali LS, Ahmed MM, Eltaweel AM, Shaikh FM, Behiry A, Hassan AE, Sabir DK, Elsherbini DMA, Ali SK, Zakari MO, Mojaddidi MA, Ali EK, Elbastawisy YM, Hadhoud S. Elkattawy HA, et al. Among authors: zakari mo. Tissue Cell. 2024 Dec 15;93:102689. doi: 10.1016/j.tice.2024.102689. Online ahead of print. Tissue Cell. 2024. PMID: 39705869
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
31 results